Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

POLB 001

Drug Profile

POLB 001

Alternative Names: HVO-001; POLB-001; UR-13870; UR-138780

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Uriach
  • Developer Centre for Human Drug Research; Palau Pharma; Poolbeg Pharma
  • Class Anti-inflammatories; Antivirals; Fluorobenzenes; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Influenza virus infections

Highest Development Phases

  • Phase I Cytokine release syndrome; Influenza virus infections
  • Discontinued Autoimmune disorders; Inflammation

Most Recent Events

  • 20 Mar 2024 Poolbeg Pharma receives patent allowance for POLB 001(Immunomodulator II) in USA
  • 09 Dec 2023 Adverse events and pharmacodynamics data from a phase-I trial in Influenza virus infections presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023) (NCT05765955)
  • 28 Nov 2023 Phase-I clinical trials in Cytokine release syndrome (unspecified route) before November 2023 (Poolberg pharma pipeline, November 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top